Xenetic Biosciences Past Earnings Performance
Past criteria checks 0/6
Xenetic Biosciences has been growing earnings at an average annual rate of 31.3%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 45.9% per year.
Key information
31.3%
Earnings growth rate
71.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 45.9% |
| Return on equity | -57.9% |
| Net Margin | -161.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable
Dec 15
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All
Dec 01Xenetic Biosciences reports Q2 results
Aug 12Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer
Aug 02Xenetic inks clinical manufacturing contract with Catalent
Jul 07Xenetic Biosciences reports Q3 results
Nov 13Revenue & Expenses Breakdown
How Xenetic Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3 | -4 | 4 | 3 |
| 30 Jun 24 | 3 | -5 | 4 | 4 |
| 31 Mar 24 | 2 | -4 | 3 | 4 |
| 31 Dec 23 | 3 | -4 | 4 | 3 |
| 30 Sep 23 | 2 | -4 | 3 | 4 |
| 30 Jun 23 | 2 | -4 | 4 | 3 |
| 31 Mar 23 | 2 | -6 | 4 | 4 |
| 31 Dec 22 | 2 | -7 | 4 | 5 |
| 30 Sep 22 | 2 | -7 | 4 | 5 |
| 30 Jun 22 | 1 | -7 | 4 | 5 |
| 31 Mar 22 | 1 | -6 | 4 | 4 |
| 31 Dec 21 | 1 | -6 | 4 | 3 |
| 30 Sep 21 | 1 | -5 | 4 | 2 |
| 30 Jun 21 | 1 | -11 | 4 | 2 |
| 31 Mar 21 | 1 | -11 | 3 | 2 |
| 31 Dec 20 | 0 | -11 | 3 | 2 |
| 30 Sep 20 | 0 | -11 | 3 | 2 |
| 30 Jun 20 | 0 | -14 | 4 | 5 |
| 31 Mar 20 | 0 | -14 | 4 | 5 |
| 31 Dec 19 | 0 | -18 | 4 | 5 |
| 30 Sep 19 | 0 | -19 | 4 | 5 |
| 30 Jun 19 | 0 | -10 | 4 | 2 |
| 31 Mar 19 | 0 | -11 | 4 | 3 |
| 31 Dec 18 | 0 | -7 | 4 | 3 |
| 30 Sep 18 | 8 | -1 | 5 | 3 |
| 30 Jun 18 | 8 | -2 | 5 | 3 |
| 31 Mar 18 | 8 | -3 | 6 | 3 |
| 31 Dec 17 | 8 | -4 | 6 | 4 |
| 30 Sep 17 | 3 | -12 | 7 | 4 |
| 30 Jun 17 | 3 | -13 | 7 | 4 |
| 31 Mar 17 | 3 | -58 | 7 | 5 |
| 31 Dec 16 | 3 | -58 | 7 | 4 |
| 30 Sep 16 | 0 | -57 | 6 | 4 |
| 30 Jun 16 | 0 | -60 | 8 | 4 |
| 31 Mar 16 | 0 | -14 | 7 | 3 |
| 31 Dec 15 | 0 | -13 | 7 | 3 |
| 30 Sep 15 | 0 | -13 | 6 | 5 |
| 30 Jun 15 | 0 | -11 | 4 | 6 |
| 31 Mar 15 | 0 | -13 | 5 | 7 |
| 31 Dec 14 | 0 | -14 | 6 | 6 |
| 30 Sep 14 | 0 | -14 | 6 | 4 |
| 30 Jun 14 | 0 | -13 | 6 | 3 |
| 31 Mar 14 | 1 | -11 | 6 | 3 |
| 31 Dec 13 | 1 | -9 | 4 | 3 |
Quality Earnings: XBIO is currently unprofitable.
Growing Profit Margin: XBIO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: XBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 31.3% per year.
Accelerating Growth: Unable to compare XBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: XBIO has a negative Return on Equity (-57.94%), as it is currently unprofitable.